Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
blog-list-cover
Recent blog posts
ChiCTR2600126426 NT-002 Vitamin D Deficiency Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
ChiCTR2600126426 NT-002 Vitamin D Deficiency Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
7 August 2026
ChiCTR2600126426 clinical trial report covering NT-002, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Read →
NCT07637162 Esreboxetine Fibromyalgia Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07637162 Esreboxetine Fibromyalgia Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
7 August 2026
NCT07637162 clinical trial report covering Esreboxetine, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Read →
CTR20262176 NHL35700 Schizophrenia Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
CTR20262176 NHL35700 Schizophrenia Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
7 August 2026
CTR20262176 clinical trial report covering NHL35700, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Read →
NCT07635511 Acalabrutinib Hematologic Neoplasms Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07635511 Acalabrutinib Hematologic Neoplasms Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
7 August 2026
NCT07635511 clinical trial report covering Acalabrutinib, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Read →
CTR20262200 Atorvastatin Calcium Hydrate/Hyzetimibe Primary hypercholesterolemia Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
CTR20262200 Atorvastatin Calcium Hydrate/Hyzetimibe Primary hypercholesterolemia Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
7 August 2026
CTR20262200 clinical trial report covering Atorvastatin Calcium Hydrate/Hyzetimibe, Phase 3, endpoints, sponsor, geography, readout timing and development
Read →
ChiCTR2600126528 Denifanstat Acne Vulgaris Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
ChiCTR2600126528 Denifanstat Acne Vulgaris Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
7 August 2026
ChiCTR2600126528 clinical trial report covering Denifanstat, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Read →
NCT07637734 Cantharidin Plantar wart Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07637734 Cantharidin Plantar wart Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
7 August 2026
NCT07637734 clinical trial report covering Cantharidin, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Read →
NCT07638553 Psilocybin Alcohol Use Disorder Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07638553 Psilocybin Alcohol Use Disorder Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
7 August 2026
NCT07638553 clinical trial report covering Psilocybin, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Read →
JPRN-jRCT2031260211 Esketamine Hydrochloride Depressive Disorder, Major Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
JPRN-jRCT2031260211 Esketamine Hydrochloride Depressive Disorder, Major Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
7 August 2026
JPRN-jRCT2031260211 clinical trial report covering Esketamine Hydrochloride, Phase 3, endpoints, sponsor, geography, readout timing and development white s
Read →
CTR20262132 QY-201 Dermatitis, Atopic Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
CTR20262132 QY-201 Dermatitis, Atopic Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
7 August 2026
CTR20262132 clinical trial report covering QY-201, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Read →
CTR20262104 Indacaterol Acetate/Glycopyrronium Bromide/ Mometasone Furoate Asthma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
CTR20262104 Indacaterol Acetate/Glycopyrronium Bromide/ Mometasone Furoate Asthma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
7 August 2026
CTR20262104 clinical trial report covering Indacaterol Acetate/Glycopyrronium Bromide/ Mometasone Furoate, Phase 3, endpoints, sponsor, geography, readout
Read →
NCT07640789 Izalontamab Brengitecan Non-small cell lung cancer stage III Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07640789 Izalontamab Brengitecan Non-small cell lung cancer stage III Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
7 August 2026
NCT07640789 clinical trial report covering Izalontamab Brengitecan, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Read →